Domain 5 of Beta 2 glycoprotein I: Friend or foe in health? Context matters

被引：0
|
作者：
Giannakopoulos, Bill [1 ,2 ]
Krilis, Steven A. [1 ,3 ]
机构：
[1] Univ New South Wales, Fac Med & Hlth, St George & Sutherland Campus,Level 2,Pitney Bldg,, Sydney, NSW 2217, Australia
[2] St George Publ Hosp, Dept Rheumatol, Kogarah, Sydney 2217, Australia
[3] St George Publ Hosp, Dept Infect Dis Immunol & Sexual Hlth, Kogarah, Sydney 2217, Australia
来源：
CLINICAL IMMUNOLOGY | 2024年 / 265卷
关键词：
Beta 2 glycoprotein I; Domain; 5; Antiphospholipid syndrome; Ischemia-reperfusion injury; Thrombosis; BETA(2)-GLYCOPROTEIN I; ANTIPHOSPHOLIPID SYNDROME; GLYCOPROTEIN-I; ENDOTHELIAL-CELLS; OXIDATIVE STRESS; LIPID-BINDING; INHIBITOR; RECEPTOR; PLASMIN; ANGIOGENESIS;
D O I：
10.1016/j.clim.2024.110282
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
Beta 2 glycoprotein I ((32GPI) is the major autoantigen in the antiphospholipid syndrome, an autoimmune disorder characterized by thrombotic and obstetric complications. The autoantibodies that target beta 2 glycoprotein I are pathogenic and contribute to disease pathogenesis. The (32GPI molecule is composed of 5 domains that are numbered 1 through to 5. Autoantibodies bind mainly to domain 1 whereas the majority of the biological functions of the (32GPI molecule in diverse processes such as apoptotic cell clearance, complement regulation, lipopolysaccharide clearance and anticoagulation have been localised to domain 5 and its unique biochemistry, reviewed in this article. The role of purified domain 5 peptide as a potential therapeutic agent in APS and ischemia reperfusion injury is discussed.
引用
收藏
页数：8
相关论文
共 50 条
  • [41] Beta 2 glycoprotein I is a substrate of thiol oxidoreductases
    Passam, Freda H.
    Rahgozar, Soheila
    Qi, Miao
    Raftery, Mark J.
    Wong, Jason W. H.
    Tanaka, Kumiko
    Ioannou, Yiannis
    Zhang, Jing Yun
    Gemmell, Rosalie
    Qi, Jian Chen
    Giannakopoulos, Bill
    Hughes, Will E.
    Hogg, Philip J.
    Krilis, Steven A.
    BLOOD, 2010, 116 (11) : 1995 - 1997
  • [42] The role of beta(2)-glycoprotein I in the antiphospholipid syndrome
    Krilis, SA
    Sheng, YH
    Kandiah, DA
    LUPUS, 1996, 5 (02) : 150 - 152
  • [43] HEREDITARY DEFICIENCY OF BETA2-GLYCOPROTEIN I
    HAUPT, H
    SCHWICK, HG
    STORIKO, K
    HUMANGENETIK, 1968, 5 (04): : 291 - &
  • [44] ANTIBODIES TO PHOSPHOLIPIDS AND TO BETA(2)GLYCOPROTEIN-I
    ARVIEUX, J
    ROUSSELL, B
    COLOMB, MG
    ANNALES DE BIOLOGIE CLINIQUE, 1994, 52 (05) : 381 - 385
  • [45] PHYSIOLOGICAL FUNCTION OF BETA 2 GLYCOPROTEIN I IN PLACENTA
    Nakamura, Hitomi
    Yagi, Kazunobu
    Komatsu, Reina
    Mimura, Kazuya
    Tabuse, Mari
    Tomimatsu, Takuji
    Endo, Masayuki
    Kimura, Tadashi
    PLACENTA, 2024, 154 : E19 - E19
  • [46] In vivo modulation of angiogenesis by beta 2 glycoprotein I
    Passam, F. H.
    Qi, J. C.
    Tanaka, K.
    Matthaei, K. I.
    Krilis, S. A.
    JOURNAL OF AUTOIMMUNITY, 2010, 35 (03) : 232 - 240
  • [47] ANTICARDIOLIPIN ANTIBODIES AND BETA-2-GLYCOPROTEIN-I
    KOIKE, T
    CLINICAL IMMUNOLOGY AND IMMUNOPATHOLOGY, 1994, 72 (02): : 187 - 192
  • [48] THE BETA-2-GLYCOPROTEIN-I AND ANTIPHOSPHOLIPID ANTIBODIES
    SHOENFELD, Y
    MERONI, PL
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 1992, 10 (02) : 205 - 209
  • [49] Immune responses against domain I of β2-glycoprotein I are driven by conformational changes: Domain I of β2-glycoprotein I harbors a cryptic immunogenic epitope
    de Laat, Bas
    van Berkel, Miranda
    Urbanus, Rolf T.
    Siregar, Berdien
    de Groot, Philip G.
    Gebbink, Martijn F.
    Maas, Coen
    ARTHRITIS AND RHEUMATISM, 2011, 63 (12): : 3960 - 3968
  • [50] Differences in exposure of the domain i epitope of beta2-glycoprotein i in commercial elisa kits for the diagnosis of the antiphospholipid syndrome
    Pelkmans, L.
    Kelchtermans, H.
    Ninivaggi, M.
    Lindhout, T.
    de Groot, P. G.
    de Laat, B.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2013, 11 : 49 - 50
12345